Fujiwara Masayuki, Kamikonya Norihiko, Odawara Soichi, Suzuki Hitomi, Niwa Yasue, Takada Yasuhiro, Doi Hiroshi, Terada Tomonori, Uwa Nobuhiro, Sagawa Kosuke, Hirota Shozo
Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Department of Radiation Oncology, Meiwa Cancer Clinic, Nishinomiya, Hyogo, Japan
Department of Radiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
J Radiat Res. 2015 May;56(3):577-82. doi: 10.1093/jrr/rrv006. Epub 2015 Mar 27.
The purpose of the present study was to determine the risk factors for developing thyroid disorders based on a dose-volume histograms (DVHs) analysis. Data from a total of 116 consecutive patients undergoing 3D conformal radiation therapy for head and neck cancers was retrospectively evaluated. Radiation therapy was performed between April 2007 and December 2010. There were 108 males and 8 females included in the study. The median follow-up term was 24 months (range, 1-62 months). The thyroid function was evaluated by measuring thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels. The mean thyroid dose, and the volume of thyroid gland spared from doses ≥10, 20, 30 and 40 Gy (VS10, VS20, VS30 and VS40) were calculated for all patients. The thyroid dose and volume were calculated by the radiotherapy planning system (RTPS). The cumulative incidences of hypothyroidism were 21.1% and 36.4% at one year and two years, respectively, after the end of radiation therapy. In the DVH analyses, the patients who received a mean thyroid dose <30 Gy had a significantly lower incidence of hypothyroidism. The univariate analyses showed that the VS10, VS20, VS30 and VS40 were associated with the risk of hypothyroidism. Hypothyroidism was a relatively common type of late radiation-induced toxicity. A mean thyroid dose of 30 Gy may be a useful threshold for predicting the development of hypothyroidism after radiation therapy for head and neck cancers.
本研究的目的是基于剂量体积直方图(DVH)分析确定发生甲状腺疾病的风险因素。对总共116例连续接受头颈部癌三维适形放射治疗的患者的数据进行了回顾性评估。放射治疗于2007年4月至2010年12月期间进行。研究纳入了108例男性和8例女性。中位随访期为24个月(范围1 - 62个月)。通过测量促甲状腺激素(TSH)和游离甲状腺素(FT4)水平评估甲状腺功能。计算了所有患者的平均甲状腺剂量以及甲状腺接受≥10、20、30和40 Gy剂量照射的体积(VS10、VS20、VS30和VS40)。甲状腺剂量和体积由放射治疗计划系统(RTPS)计算得出。放射治疗结束后1年和2年时,甲状腺功能减退的累积发生率分别为21.1%和36.4%。在DVH分析中,平均甲状腺剂量<30 Gy的患者甲状腺功能减退的发生率显著较低。单因素分析表明,VS10、VS20、VS30和VS40与甲状腺功能减退的风险相关。甲状腺功能减退是一种相对常见的晚期放射诱导毒性类型。30 Gy的平均甲状腺剂量可能是预测头颈部癌放射治疗后甲状腺功能减退发生的一个有用阈值。